TW201210509A - Anti-allergy lactic acid bacteria - Google Patents

Anti-allergy lactic acid bacteria Download PDF

Info

Publication number
TW201210509A
TW201210509A TW100139644A TW100139644A TW201210509A TW 201210509 A TW201210509 A TW 201210509A TW 100139644 A TW100139644 A TW 100139644A TW 100139644 A TW100139644 A TW 100139644A TW 201210509 A TW201210509 A TW 201210509A
Authority
TW
Taiwan
Prior art keywords
strain
lactobacillus
lactic acid
allergic
cells
Prior art date
Application number
TW100139644A
Other languages
Chinese (zh)
Other versions
TWI386163B (en
Inventor
Wei-Chi Su
Pei-Shan Hsieh
Yi-Chun Tsai
Chyi-Jang Wu
Yi-Chun Chen
Chung-Wei Kuo
Chiung-Ying Yang
Original Assignee
Promd Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promd Biotech Co Ltd filed Critical Promd Biotech Co Ltd
Priority to TW100139644A priority Critical patent/TWI386163B/en
Publication of TW201210509A publication Critical patent/TW201210509A/en
Application granted granted Critical
Publication of TWI386163B publication Critical patent/TWI386163B/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention described relates to novel strains of lactic acid bacteria and to novel compositions containing a novel strain or strains not previously known to be useful in anti-allergy. The composition may be in the form of foodstuffs or in the form of pharmaceutical compositions. The invention described how to screen the strains of lactic acid bacteria can regulate the immune balance between Th1 type and Th2 type.

Description

201210509 六、發明說明: 【發明所屬之技術領域】 本發明係有關應用在食品或醫藥之抗 合物及其應用於抗過敏能力上用途。 礼酉文菌函株、,且 【先前技術】 近幾年來過敏疾病有逐年增加的趨勢,又从曰1 膚炎、過敏性鼻炎和支氣管性氣喘的發生^; 目前認為過敏疾病的發生可能與文明的進步有月广的 污染和感染誠少都可能是導致過敏雜增加的— 因。而目前應用在氣喘的治療主要是靠藥物治療 專。但疋,包括抗發炎樂物和氣官擴張劑在内的 無法真正的改變過敏免疫反應,所以只能說是治以$ 法。而唯一能夠說是改變過敏免疫體質的治療方式: 的減敏療法,但是減敏治療通常需要較長的一段時間,而且= 時會出現-些副作用’因此也不是所有的病人都能夠使用。 有關過敏疾病的增加’目前認為跟大環境的變化有密切 係,特別是在環境方面有更明顯的關係。人體腸道中的&生 會刺激免疫系統作用,但如果在日常生活中的食品含有^生 或是類固醇含量太尚,都會導致腸道内的益生菌降低,因而^ 法有效地刺激免疫細胞中第一型τ輔助細胞(Thl )的生成, 這些第一型τ輔助細胞的生成與第二型T辅助細胞(Th2)相 關的過敏疾病發生有著密切關連。因此,如果能利用保健食品 來刺激我們的免疫系統,誘發出可以調節過敏免疫反應的if 型免疫反應平衡過敏所引發Th2型免疫反應,將可達^改盖、尚 敏體質的效果。 在人類應用微生物的歷史上,乳酸菌的應用起源相當早。 從早期乳製品的加工上發現,食用乳酸菌發酵之食品,^助於 改善人類腸胃道疾病的發生率以及延長平均壽命的現象。由 201210509 ^相始研究探討乳_在促進人體健康中所能 潮不斷的發酵,於西元1965年由L%觀吏等 k出Pr〇b1〇tlc—益生菌的概念’成為功能性乳酸菌的統稱。 效果之產⑽具有職料的健康 效果:雖財數以4計的乳酸關株存在自然界,但僅有少數 株具有抗過敏的㈣。少數這些_株所具有的耐酸與 而’ /孤旎力,吸附黏膜表皮細胞之能力及在通過腸胃道後仍可 存活的能力等特性,是筛選有促進鋪效果_株時的重要依 j 康寺至5日僅有少數幾株經證明其具有抗過敏健康效果之 礼酸菌菌株被確認出來,而乳酸菌的對身體健康的功能在於菌 株(strain)的特異性而非菌種(species),此種對於人之身體健康 有特殊功效之菌株稱為功能性益生菌(Guidelines f〇r the201210509 VI. Description of the Invention: [Technical Field to Which the Invention Is Applicable] The present invention relates to an application to a food or medicine and its use in anti-allergic ability. Livure fungi, and [prior art] Allergic diseases have increased year by year in recent years, and from the occurrence of phlegm, allergic rhinitis and bronchial asthma ^; The progress of civilization, with a wide range of pollution and infection, may lead to an increase in allergies. At present, the treatment of asthma is mainly based on drug treatment. However, cockroaches, including anti-inflammatory and gas-swelling agents, can't really change the allergic immune response, so it can only be said to be treated by $. The only treatment that can be said to change the allergic immune constitution: desensitization therapy, but desensitization treatment usually takes a long time, and = some side effects will occur - so not all patients can use. The increase in allergic diseases is currently considered to be closely related to changes in the environment, especially in terms of the environment. The &intestines in the human gut stimulate the immune system, but if the food in daily life contains too much or too much steroid content, it will lead to a decrease in probiotics in the intestine, thus effectively stimulating immune cells. The production of a type 1 τ helper cell (Thl), which is closely related to the development of allergic diseases associated with type 2 T helper cells (Th2). Therefore, if we can use health foods to stimulate our immune system, and induce a Th2-type immune response caused by a balanced type of allergic immune response that can regulate allergic immune reactions, it will be able to achieve the effect of changing the body and sensitive body. In the history of human applied microorganisms, the application of lactic acid bacteria originated quite early. From the processing of early dairy products, it has been found that the consumption of foods fermented by lactic acid bacteria helps to improve the incidence of human gastrointestinal diseases and prolong the average life expectancy. From the beginning of 201210509, we will discuss the continuous fermentation of milk in the promotion of human health. In 1965, the concept of "Pr〇b1〇tlc-probiotics" was made by L% Guanlan, and became the generic name of functional lactic acid bacteria. . The effect of the production (10) has the health of the material effect: Although the number of lactic acid is 4 in the natural world, only a few strains have anti-allergic (four). A small number of these strains have the characteristics of acid resistance and '/ orphan force, ability to adsorb mucosal epithelial cells and ability to survive after passing through the gastrointestinal tract, and are important for screening and promoting the effect of spreading. There were only a few strains of Phytophthora strains that proved to have anti-allergic health effects on the 5th, and the function of lactic acid bacteria on body health lies in the specificity of the strain rather than the species. Such a strain that has a special effect on human health is called a functional probiotic (Guidelines f〇r the

evaluation of probiotics in food ; Report of joint FAO/WHO woridng group on drafting guidelines for the evaluation of probiotics in food ; London Ontario, Canada April 30 and May 1 2002 : 1-7)。 ’ 過敏疾病,例如過敏性濕疹、蓴麻疹、反覆發作的過敏性 鼻炎及過敏性氣喘’在台灣及其他已開發國家已成為嚴重的社 會問題。之所以形成過敏疾病的流行程度的提升,是有原因 的’這眾所皆知的衛生假說為:嬰幼兒接觸免疫刺激病原體的 機會愈少’愈容易引發過敏相關疾病的產生(Strachan,1989)。 過敏疾病發生時,人體内的免疫反應會使Thl細胞數量下降, 連續產生多種細胞激素促使免疫反應朝向Th2途徑,形成體液 免疫反應,例如IgE的產生及嗜伊紅血球過多等(Romagnani, 1994; Holt, 1995)。 在愛沙尼亞及瑞典這兩個國家的孩童人口中發現,有過敏 疾病的孩童腸道内的乳酸桿菌比無過敏疾病的孩童要少 (Bjo“rksten et al.,1999)。乳酸桿菌被認為可促進Thl的免疫反 201210509 應進而改善過敏症狀(Cross etal., 2001)。再者,以印白蛋白誘 發小鼠過敏的動物實驗模式中發現,讓小鼠以口服方式食用熱 處理後的Lactobacillus casei strain Shitota,可抑制小鼠血清中 IgE的含量(Matsuzaki et al” 1998)。此外,以酪蛋白誘發小鼠 過敏的動物實驗模式中證明,腹腔注射熱處理後的Evaluation of probiotics in food ; Report of joint FAO/WHO woridng group on drafting guidelines for the evaluation of probiotics in food ; London Ontario, Canada April 30 and May 1 2002 : 1-7). Allergic diseases such as allergic eczema, urticaria, recurrent allergic rhinitis and allergic asthma have become serious social problems in Taiwan and other developed countries. There is a reason for the increase in the prevalence of allergic diseases. 'This well-known health hypothesis is: The less chance that infants and young children will be exposed to immune stimuli, the more likely they are to cause allergic-related diseases (Strachan, 1989) . When an allergic disease occurs, the immune response in the human body will decrease the number of Th1 cells, and continuously produce a variety of cytokines to promote the immune response toward the Th2 pathway, forming a humoral immune response, such as the production of IgE and excessive eosinophils (Romagnani, 1994; Holt , 1995). In the children of Estonia and Sweden, children with allergic diseases have fewer lactobacilli in the gut than those without allergies (Bjo “rksten et al., 1999”. Lactobacillus is thought to promote Thl The immunization against 201210509 should further improve allergy symptoms (Cross et al., 2001). Furthermore, in an animal model of albumin-induced mouse allergy, it was found that the mice were orally administered Lactobacillus casei strain Shitota after heat treatment. It can inhibit the content of IgE in mouse serum (Matsuzaki et al) 1998). In addition, the animal model of casein-induced mouse allergy was demonstrated in the intraperitoneal injection of heat-treated

Lactobacillus plantarum L-137,也可抑制 IgE 的產生(Murosaki et al.,1998)。由豕草花粉過敏引起的過敏症狀,口服 Enterococcus faecalisFK-23萃取物,可使腹膜内聚集的嗜伊紅 血球細胞量減少(81^11^(^61此,2003)。人體的臨床試驗中,於 待產期間服用Lactobacillus rhamnosus strain GG,發現在出生 後兩年(Kallioma”ki et al.,2001)及嬰兒期後(Kallioma..ki et al,, 2003) ’可降低嬰幼兒產生過敏性濕疹的風險及發生率。’Lactobacillus plantarum L-137 also inhibits the production of IgE (Murosaki et al., 1998). The allergic symptoms caused by hay fever pollen allergy, oral Enterococcus faecalis FK-23 extract, can reduce the amount of eosinophils accumulated in the peritoneum (81^11^(^61, 2003). In human clinical trials, Taking Lactobacillus rhamnosus strain GG during labor, it was found that two years after birth (Kallioma"ki et al., 2001) and after infancy (Kallioma..ki et al, 2003) can reduce allergic eczema in infants and young children. Risk and incidence.'

Lactobacillus rhamnosus 19070-2 及 Lactobacillus reuteri DSM122460也可以適度地改善患有異位性皮膚炎的孩童其嚴 重溼疹的過敏症狀(R0Senfeldt et al., 2003)。 【發明内容】 本發明一方面廣義的包括由下列任一種生物性純培養 物.嗜酸乳桿囷(Lactobacillus acidophilus)PM-A0002 菌株,民 國九十五年二月二十三日食品工業發展研究所寄存編號 BCRC 910308、加氏乳酸桿菌(Lactobacillus gasseri)PM-A0005 菌株,民國九十五年一月十一日食品工業發展研究所寄存編號 BCRC 910304、唾液乳酸桿菌(Lact〇bacillus salivarius subsp salicinms)PM-A0006菌株,民國九十五年一月十一日食品工業 發展研究所寄存編號BCRC 910305、約氏乳酸桿菌 (Lactobacillusjohnsonii)PM-A0009菌株,民國九十五年十月十 七曰食品工業發展研究所寄存編號BCRC 91〇336、嗜酸乳桿 菌(Lactobacillus acidophilus)PM-A0013 菌株,民國九十五年二 月二十三日食品工業發展研究所寄存編號BCRC 910309。與 生理上可接受的賦形劑或稀釋劑組成之組合物。 201210509 在-項具體實施例中,該組合物含有一種或一種以上該等 菌株’如生理上可接受的卿贼稀_是―種食品為較佳之 形式,該食品可以是醱酵乳、優格、乳酪、乳製飲品、乳粉、 茶飲料或咖啡中任何-種較佳,又或者,該組合物是醫藥組合 物’且其賦㈣彳或稀釋劑應為醫藥上可接受之則彡劑或稀釋 劑0 遐貰苑例中,增強抗過敏能力之生理上可接受 ίΓΙΐ—種菌株之同種或突變種之生物性純培養物:魏乳 ^ΡΜ-Α0002菌株、加氏乳酸桿菌ρΜ_Α〇〇〇5菌株、唾液乳 ^ =:06菌株、約氏乳酸桿3 ΡΜ·Α_9菌株或嗜酸 礼桿菌ΡΜ-Α0013菌株。 具體實施例中,本發日月可廣義的包括經由促進 玻)或干擾素7調控™型免疫反應而抑制免疫 ;g改善迦型免疫反應過剩的過敏現象,其係對哺 -種===== = ;稀釋劑呈組合物的形式投予與 請釋劑為食品較佳,該食品是_乳、優格、^ ^飲:,、乳粉、茶飲料或咖啡中任—種較佳 ^么 物疋醫藥組合物’且賊形劑或轉 上 ?、’二 形劑或稀釋劑。 卿料社可接受之賦 明之i ϊ廣義的包括本巾請案㈣書中分開,气 何包含料料&二 ;^口口 I者或更夕者之任何或全部組合,且若太々张、十-完整事物已於與本發==斤, 201210509 【實施方式】 <本發明可廣義的包括由下列任—種生物性純培養物: 礼桿菌PM-A0002菌株,民國九十五年二月二十三日食 ,展研究所寄存職BCRC 9_8、械乳轉g ρΜ:〇〇〇5 囷株,關九十五年-肝-日食以業發展研究所寄存編號 BCRC 910304、唾液乳酸桿菌菌株,民國九十五年一月十一日 食品工業發展研究所寄存編號BCRC 910305、約氏乳酸桿菌 PM-A00G9菌株,民國九十五年十月十七日食品卫業發展研究 所寄存編號BCRC 910336、嗜酸乳桿菌ΡΜ_Α〇〇13菌株,民 國九十五年一月一十二日食品工業發展研究所寄存編 BCRC 910309。 許多文獻指出增加第一型T細胞細胞激素包括細胞間白 素(IL-12)、干擾素γ (iFN-gamma)的分泌增加,可以有效改善 過敏症狀;進一步的研究也指出特定的乳酸菌株和樹狀細胞上 類鐸受體(Toll-like receptor)結合,活化細胞内的轉譯蛋白移至 核内而釋放大量細胞激素,屬於先天免疫的一環,因此某些特 定的乳酸菌菌種借由其細胞壁多醣類物質如peptid〇glycan、 lipopolysaccharide、polysaccharide 等,經先天免疫系統,確實 能活化T細胞的發育。 、 菌株名 編號 曰期 嗜酸乳桿菌PM-A0002 BCRC910308 2006年02月23日 加氏乳酸桿菌PM-A0005 BCRC910304 2006年01月11日 唾液乳酸桿菌PM-A0006 BCRC910305 2006年01月11日 約氏乳酸桿菌PM-A0009 BCRC910336 2006年10月17日 嗜酸乳桿菌PM-A0013 BCRC910309 2006年02月23日 該五株細菌菌株之冷凍乾燥培養物已寄存在台灣食品工 業發展研究所,地址為:中華民國新竹市食品路331號。寄存 之洋細資料如表1所示: 201210509 表1 如上所列專利寄存的這五株乳酸菌已發現具有抗過敏的 能力’包括對於異位性皮膚炎、蓴麻疹、過敏性鼻炎、食物過 敏及氣喘的症狀有減缓及治療的功能。 實例1 :五株抗過敏乳酸菌之形態學及一般性質。 ,據16S rDNA序列分析及API細菌鑑定系統分析結果來 確認菌株在分類學上的特徵。發現,東宇菌株編號?]^_^〇〇〇2 ,,酸乳桿菌;東宇菌株編號PM-A0005為加式乳酸桿菌;東 宇菌株編號PM-A0006為唾液乳酸桿菌;東宇菌铁 ϋ·09為約式乳酸桿菌及東宇ϋ株編號PM-AGG13為嗜酸U 桿菌。此五株菌株在形態學及一般性質上的特徵詳細列^表 嗜酸乳桿菌PM-A0002 : 呈繼編,高形,通常單 好氧及職觸n,運動性,在 …±lc,屬於兼性 Arr rt·奋I 碰 4旦 ϋ τ%、, . _ " -- 加氏乳酸桿菌PM-A0005 : 於MRS培義液培養時短桿狀 獨出現、成對或成短鏈狀。 長,通常單 革蘭氏染色桿g,不生成孢子,不 好氧及厭氧環境均能生長,最適宜 ^_及運動性,在 屬於兼性 唾液乳酸桿菌ΡΜ-Α0006 . ___ 於MRS培義液培養時,菌體呈短桿狀, 成對短鏈狀。 —碼呈圓形’通常單獨出現、 革蘭氏染色陽性桿菌,不生成 長二氡化酶及運動性’在 唾液乳酸桿時不產生氣! 201210509 約氏乳酸桿菌PM-A0009: -端呈圓形,通常成 W狀或稍長, 革蘭氏染色陽性桿菌,不生成抱子 好氧及厭氧環境均能生長,最適宜的生長化酶及運動性’在 錢»^!葡糖代謝時不產生氣體:j 37土1 C,屬於兼性 嗜酸乳桿菌PM-A0013 於MRS培養液培養時,里短或稍長-山 革蘭氏染色陽性桿菌,不生成孢子,不 呈方形’成鏈狀。 子=及厭錢_能生長,最適宜的生長溫度為π破 謝時不產生氣體 表 2 ~ — ~ =2 :抗過敏乳酸菌對促進干擾素γ的分泌調控加型 力的仙(以周邊血液單核球細胞為體外功效驗證平 檢視五株抗過敏乳酸菌株,嚷g曼乳桿菌pM_A〇〇〇2菌株、 2氏乳酸料ΡΜ·Α_5 g株、麵魏湖pM_A_6菌 株、約氏乳酸桿菌PM-A0009菌株或嗜酸乳桿菌pM_A〇〇 株對™型免疫能力的增進效果,其係觀人綱邊血液^ 球與抗過敏乳酸菌共同培養後測定干擾素γ的分泌量,來篩選 具有抗過敏能力的菌株。使用如下之實驗步驟: I抽取適當人類血液量每次約2〇〇mi。 2·取等比例之血球分離液(Ficoll-paque)與血液在18_2〇。〇以 400g離心30-40分鐘。 3. 取人類周邊血液白血球(Peripheral blood mononuclear cell, PBMC)層’緩衝溶液清洗細胞2-3次後,以適當之培養基(例 如RPMI-1640)懸浮細胞。 4. 將細胞與已活化3天之乳酸菌株以1 : 1〇比例共同培養48 201210509 小時。 5.收取細胞培養之上清液。利用酵素免疫分析法(ELISA)偵測 干擾素7(IFN-gamma)在上清液中的含量。 數據之統§十分析如表3及第1圖所示,以Mean 士 SD表示 之。第1圖所示為當分別以1〇6至1〇8個cfU嗜酸乳桿菌 (Lactobacillus acidophilus)PM-A0002 菌株、加氏乳酸桿菌 (Lactobacillus gasseri)PM-A0005 菌株、唾液乳酸桿菌 (Lactobacillus salivarius subsp. salicinius)PM-A0006 菌株、約氏 乳酸桿菌(Lactobacillus johnsonii)PM-A0009菌株或嗜酸乳桿菌 (Lactobacillus acidophilus)PM-A0013 菌株與 1〇5 至 1〇7個人類周 邊血液白血球(PBMC)共同共同培養48小時,收取細胞上清 液’以酵素免疫分析法偵測干擾素γ (IFN-gamma)在上清液中 的含量。其中以無抗過敏功能乳酸菌(Lactobacillus casd BCRC12249)為負控制組’ PHA為正控制組,偵測干擾素γ受 刺激濃度。結果顯示試驗組可以顯著的刺激人類周邊血液白血 球(PBMC)分泌干擾素γ與負控制組有顯著性差異。表3為分 別以五株抗過敏菌株與人類周邊血液單核球培養,刺激干擾素 菌株名稱 干擾素γ的分泌量(pg/ml) 嗜酸乳桿菌 PM-A0002 19833±2767 j口式导述桿菌PM-A0005 46625±3624 唾液標简ΡΜ-ΑΟΟΟό 25850±2347 iiML 酸桿菌 ΡΜ-Α0009 25725±2008 菌 ΡΜ-Α0013 17416±2803 (L. casei BCRC 12249) 11±2.3 去控制組(positive control)_ __ 44666+2488_^ 表3 實例3 ;抗過敏乳酸菌對促進細胞間白素(IL_12)的分泌調 201210509 控Thl型免疫能力的作用(以樹狀細胞如付也化⑵丨丨為體外功效 驗證平台)。 檢視五株抗過敏乳酸菌株,嗜酸乳桿菌pM_A〇〇〇2菌株、 加氏乳酸桿菌PM-A0005菌株、唾液乳酸桿菌PM_A〇〇〇6菌 株、約氏乳酸桿菌PM-A0009菌株或嗜酸乳桿菌PM-A0013菌 株對Thl型免疫能力的增進效果,其係測定人類樹狀細胞與抗 過敏乳酸菌共同培養後測定細胞間白素(IL_12)的分泌量,來篩 選具有抗過敏能力的菌株。使用如下之實驗步驟: 1. 抽取適當人類血液量每次約2〇〇mi。 2. 取等比例之血球分離液(Fic〇u_paque)與血液在18_2〇。〇以 400g離心30-40分鐘。 3. 取人類周邊血液白血球(pbMC)層,緩衝溶液清洗細胞2-3 认後’以適當之培養基(例如RPMj_ 164〇)懸浮細胞。 4. 人類周邊血液白血球(PBMC)細胞以CD14+ microbeads (MiniMACS system)將細胞之CD14+單核球純化。 5. 以細胞激素(IL-4)及生長激素GM-CSF刺激細胞分化成樹狀 細胞,6-7天的培養時間’將已分化之樹狀細胞收集。 6. 將抗過敏乳酸菌株在共同培養之前3天活化,之後以1〇〇。〇 熱致死乳酸菌株30分鐘。 7. 將樹狀細胞與已熱致死之乳酸菌株以1 : 10比例共同培養 48小時。 8. 收取細胞培養之上清液。利用酵素免疫分析法(ELISA)偵測 細胞間白素(IL-12)在上清液中的含量。 數據之統計分析如表4及第2圖所示,以Mean士 SD表示 之。第2圖所示為當分別以熱殺死1〇6至1〇8個嗜酸乳桿 菌(Lactobacillus acidophilus)PM-A0002 菌株、加氏乳酸桿菌 (Lactobacillus gasseri)PM-A0005 菌株、唾液乳酸桿菌 (Lactobacillus salivarius subsp. salicinius)PM-A0006 菌株、約氏 201210509 乳酸桿菌(Lactobacillus johnsonii)PM-A0009菌株或嗜酸乳桿菌 (Lactobacillus acidophilus)PM-A0013 菌株與 105 至 1〇7 個人類樹 狀細胞(dentritic cell)共同培養48小時,收取細胞上清液,以 酵素免疫分析法偵測細胞間白素(IL-12)在上清液中的含量。其 中以無抗過敏功能乳酸菌(Lactobacillus casei BCRC12249)為 負控制組’ PHA為正控制組,偵測細胞間白素(IL_12)受刺激 濃度。結果顯示試驗組可以顯著的刺激人類樹狀細胞分泌細胞 間白素(IL-12)與負控制組有顯著性差異。表4所示為分別以五 株熱致死抗過敏菌株與樹狀細胞培養,刺激細胞間白素(IL_12) 菌株名稱 細胞間白素(IL-12)的分泌量 (pg/ml) _嗜酸乳桿菌 PM-A0002 15019±569 加式乳酸桿菌 PM-A0005 19222士212 唾液乳酸稈菌PM-A0006 18625士365 約氏乳酸桿菌PM-A0009 18291士39 嗜酸乳桿菌 PM-A0013 17836±168 負控制組(L. casei BCRC 12249、 80±15 正控制組(positive control) 13786±341 表4 貫例4 :抗過敏乳酸菌耐胃酸膽鹽試驗。 檢視五株抗過敏乳酸菌株,嗜酸乳桿菌pM_A〇〇〇2菌株、 加氏乳酸桿菌PM-A0005菌株、唾液乳酸桿菌pM_A〇〇〇6菌 約氏乳酸桿菌PM-A0009菌株或嗜酸乳桿菌PM_A〇〇13菌 可否具有通過胃酸膽鹽考驗的能力順利在腸道發揮其抗過 敏的功能,試驗流程如下: 1·將五株抗過敏乳酸菌活化3天。 2.取1 mL菌液計算原始菌數,剩餘之乳酸菌以5〇〇g離心1〇 12 201210509 :知加入去離子水清洗乳酸菌2-3次。 活細,出二水清洗2蝴’計算存 5· 餘囷液離心後沈澱物再以含 丄於 37心 活細胞數,至4小時培^間^^洗2蝴,計算存 7. 酸g生長速率’計算乳酸g對胃離膽越之 樣品中乳酸菌在胃酸及膽鹽存在下,菌株生長是又否受 圖所分析整理於表5及第3圖所示,第3 it酸乳酸菌在培養基的活化後,總菌 敏之專利處理’菌數明顯下降許多;調節過 溶液及專:=6在、^^ 趟Hi而登明對胃酸具有耐受性,但將菌株經由膽 ^處=,賴囷株有些許的下降,但對膽鹽仍有耐受性,註 之此五株乳酸菌株可以通過人體消化系統嚴格環境 ϊί酸S為以㈤值2·5的鹽酸與抗過敏乳酸菌混合測驗Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM122460 can also moderately improve the allergic symptoms of severe eczema in children with atopic dermatitis (R0Senfeldt et al., 2003). SUMMARY OF THE INVENTION In one aspect, the present invention broadly includes any of the following biologically pure cultures, Lactobacillus acidophilus PM-A0002 strain, and food industry development research on February 23, 1995. Registered number BCRC 910308, Lactobacillus gasseri PM-A0005 strain, January 11, 1995 Food Industry Development Institute registration number BCRC 910304, Lactobacillus salivarius subsp salicinms PM-A0006 strain, the Food Industry Development Institute of the Republic of China on January 11, 1995, registered number BCRC 910305, Lactobacillus johnsonii PM-A0009 strain, October 17th, the Republic of China food industry development The Institute registered number BCRC 91〇336, Lactobacillus acidophilus PM-A0013 strain, and the Food Industry Development Institute registered number BCRC 910309 on February 23, 1995. A composition consisting of a physiologically acceptable excipient or diluent. 201210509 In a specific embodiment, the composition contains one or more such strains, such as a physiologically acceptable thief, which is a preferred form of food, which may be fermented milk, yogurt, Any of the cheese, the dairy drink, the milk powder, the tea beverage or the coffee is preferably, or alternatively, the composition is a pharmaceutical composition and the bismuth or diluent should be a pharmaceutically acceptable elixirs or Diluent 0 In the case of 遐贳 遐贳 , , , , , , , , , , , 生物 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强 增强5 strain, saliva milk ^ =: 06 strain, Yogurt lactic acid rod 3 ΡΜ · Α _9 strain or E. acidophilus ΡΜ - Α 0013 strain. In a specific embodiment, the present day and the month can broadly include inhibiting immunity by regulating the type III immune response by promoting the glass or interferon 7; g improving the allergic phenomenon of excessive immune reaction of the type G, and the pair is feeding the seed === ===; The diluent is preferably administered in the form of a composition and the release agent is a food, and the food is preferably _milk, yogurt, tea, or coffee. ^ 疋 疋 pharmaceutical composition 'and thief-shaped agent or turn on?, 'dix-shaped agent or thinner. I can accept the definition of the i ϊ ϊ 包括 包括 包括 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本 本Zhang, Shi-Complete things have been with the present hair == Jin, 201210509 [Embodiment] <The present invention can broadly include any of the following biological pure cultures: Pseudomonas PM-A0002 strain, Republic of China ninety-five On February 23, the food, exhibition research institute BCRC 9_8, mechanical milk transfer g ρΜ: 〇〇〇5 囷 ,, off the ninety-five years - liver-eclipse industry development institute registration number BCRC 910304, Lactobacillus saliva strain, the Food Industry Development Institute of the Republic of China on January 11, 1995, registered number BCRC 910305, Lactobacillus johnsonii PM-A00G9 strain, October 17th, 1995 Food Safety Development Institute The registration number BCRC 910336, Lactobacillus acidophilus ΡΜ_Α〇〇13 strain, registered in the Food Industry Development Institute of the Republic of China on January 12, BCRC 910309. Many literatures have pointed out that increasing the secretion of first-type T-cell cytokines including interleukin (IL-12) and interferon-gamma (iFN-gamma) can effectively improve allergy symptoms; further studies have pointed out specific lactic acid strains and trees. The binding of Toll-like receptors on the spheroid cells, the transfer of the transgenic proteins in the activated cells to the nucleus and the release of a large number of cytokines, is a part of innate immunity, so some specific lactic acid bacteria species have more cell walls. Sugar substances such as peptid〇glycan, lipopolysaccharide, polysaccharide, etc., through the innate immune system, can indeed activate the development of T cells. , strain name number Lactobacillus acidophilus PM-A0002 BCRC910308 February 23, 2006 Lactobacillus kawaii PM-A0005 BCRC910304 January 11, 2006 Lactobacillus saliva PM-A0006 BCRC910305 January 11, 2006 Yogurt Bacillus PM-A0009 BCRC910336 October 17, 2006 Lactobacillus acidophilus PM-A0013 BCRC910309 The frozen-dried culture of the five bacterial strains has been deposited at the Taiwan Food Industry Development Institute at the address of the Republic of China on February 23, 2006. No. 331, Food Road, Hsinchu City. The details of the deposit are shown in Table 1: 201210509 Table 1 The five strains of lactic acid bacteria deposited in the above listed patents have been found to have anti-allergic ability' including atopic dermatitis, urticaria, allergic rhinitis, food allergies and Symptoms of asthma have a function of slowing and treating. Example 1: Morphology and general properties of five anti-allergic lactic acid bacteria. According to the 16S rDNA sequence analysis and the results of the API bacterial identification system analysis, the taxonomic characteristics of the strain were confirmed. Found that Dongyu strain number? ]^_^〇〇〇2,, Lactobacillus acidophilus; Dongyu strain number PM-A0005 is Lactobacillus added; Dongyu strain number PM-A0006 is Lactobacillus saliva; Dongyu bacteria Tielu·09 is about lactic acid Bacillus and Dongyu strain No. PM-AGG13 are U. acidophilus. The morphological and general characteristics of the five strains are listed in detail. Table Lactobacillus acidophilus PM-A0002: is a successor, high-profile, usually single aerobic and occupational touch n, motility, in...±lc, belongs to Facultative Arr rt · Fen I touch 4 denier τ%,, . _ " -- Lactobacillus bergii PM-A0005 : Short rod-shaped, paired or short-chained when cultured in MRS culture. Long, usually single Gram staining rod g, does not produce spores, can grow in both aerobic and anaerobic environments, most suitable for ^_ and motility, in the facultative salivary bacillus ΡΜ-Α0006. ___ in MRS training When the liquid is cultured, the cells are short rod-shaped and paired in a short chain. - The code is rounded 'usually appears alone, Gram-positive bacilli, does not produce long diminidase and is motility'. No gas is produced in the saliva lactic acid rod! 201210509 Lactobacillus johnsonii PM-A0009: - The end is round, usually W-shaped or slightly longer, Gram-positive bacilli, can grow without augmentation of aerobic and anaerobic environment, the most suitable growth enzyme And exercise 'in money»^! Glucose metabolism does not produce gas: j 37 soil 1 C, belongs to facultative Lactobacillus acidophilus PM-A0013 when cultured in MRS medium, short or slightly longer - Mountain Gram Stain-positive bacilli, do not produce spores, do not form a square 'chain. Sub = and disgusting money _ can grow, the most suitable growth temperature is π when the gas is not produced. Table 2 ~ ~ ~ = 2: anti-allergic lactic acid bacteria to promote the secretion of interferon γ to increase the force of the immortal (to the peripheral blood Mononuclear cells were tested for in vitro efficacy. Five strains of anti-allergic lactic acid strains, Lactobacillus pneumoniae pM_A〇〇〇2 strain, 2 lactic acid ΡΜ·Α_5 g strain, Weiwei lake pM_A_6 strain, Lactobacillus johnii PM -A0009 strain or Lactobacillus acidophilus pM_A〇〇 strain enhances the immunity of TM type, and the amount of interferon γ is measured by co-cultivation of the blood and the anti-allergic lactic acid bacteria. The ability of the strain. Use the following experimental steps: I extract the appropriate human blood volume about 2 〇〇mi each time. 2. Take an equal ratio of Ficoll-paque and blood at 18_2 〇. 40 minutes. 3. Wash the cells 2-3 times with the Peripheral blood mononuclear cell (PBMC) layer buffer solution and suspend the cells in a suitable medium (eg RPMI-1640). 4. Activate the cells with activated cells. 3-day lactic acid strain 1 : 1 〇 ratio co-culture 48 201210509 hours. 5. Collect supernatant from cell culture. Use enzyme immunoassay (ELISA) to detect the content of interferon 7 (IFN-gamma) in the supernatant. § Ten analysis is shown in Table 3 and Figure 1, represented by Mean Shi SD. Figure 1 shows the strains of Lactobacillus acidophilus PM-A0002 at 1〇6 to 1〇8, respectively. , Lactobacillus gasseri PM-A0005 strain, Lactobacillus salivarius subsp. salicinius PM-A0006 strain, Lactobacillus johnsonii PM-A0009 strain or Lactobacillus acidophilus The PM-A0013 strain was co-cultured with 1〇5 to 1〇7 human peripheral blood leukocytes (PBMC) for 48 hours, and the cell supernatant was collected. The enzyme immunoassay was used to detect interferon gamma (IFN-gamma) in the supernatant. The content of the liquid, in which the anti-allergic lactic acid bacteria (Lactobacillus casd BCRC12249) was used as the negative control group 'PHA as the positive control group, the interferon γ was stimulated to detect the concentration. The results showed that the test group can significantly stimulate people. Peripheral blood leukocytes (PBMC) secreted interferon gamma and the negative control group were significantly different. Table 3 shows the secretion of interferon γ (pg/ml) by five anti-allergic strains and human peripheral blood mononuclear cells, respectively. The Lactobacillus acidophilus PM-A0002 19833±2767 j-mouth Bacteria PM-A0005 46625±3624 Saliva standard ΡΜ-ΑΟΟΟό 25850±2347 iiML Acid bacillus ΡΜ-Α0009 25725±2008 ΡΜ-ΡΜ0013 17416±2803 (L. casei BCRC 12249) 11±2.3 to control group (positive control) __ 44666+2488_^ Table 3 Example 3; Anti-allergic lactic acid bacteria promote the secretion of intercellular white pigment (IL_12) 201210509 The role of Thl-type immunity (to the dendritic cells such as Fuhua (2) 体外 for in vitro efficacy verification platform ). Five anti-allergic lactic acid strains, Lactobacillus acidophilus pM_A〇〇〇2 strain, Lactobacillus calyceii PM-A0005 strain, Lactobacillus salivarius PM_A〇〇〇6 strain, Lactobacillus johnsonii PM-A0009 strain or cola sour milk The effect of the strain PM-A0013 on the immunity of Th1 type is determined by measuring the secretion amount of intercellular melanin (IL_12) after co-culture of human dendritic cells with anti-allergic lactic acid bacteria to select strains having anti-allergic ability. Use the following experimental steps: 1. Draw appropriate human blood volume approximately 2 〇〇mi each time. 2. Take an equal ratio of blood cell separation solution (Fic〇u_paque) and blood at 18_2〇. Centrifuge at 400g for 30-40 minutes. 3. Take the human peripheral blood leukocyte (pbMC) layer, wash the cells with buffer solution 2-3 and then suspend the cells in a suitable medium (eg RPMj_164〇). 4. Human peripheral blood leukocyte (PBMC) cells were purified from CD14+ mononuclear cells of the cells by CD14+ microbeads (MiniMACS system). 5. The cells were differentiated into dendritic cells by cytokines (IL-4) and growth hormone GM-CSF, and the differentiated dendritic cells were collected at a culture time of 6-7 days. 6. The anti-allergic lactic acid strain was activated 3 days before co-cultivation, followed by 1 〇〇. 〇 Heat lethal lactic acid strain for 30 minutes. 7. The dendritic cells were co-cultured with the heat-killed lactic acid strain at a ratio of 1:10 for 48 hours. 8. Collect the supernatant from the cell culture. Enzyme immunoassay (ELISA) was used to detect the content of intercellular white pigment (IL-12) in the supernatant. The statistical analysis of the data is shown in Table 4 and Figure 2, and is represented by Mean Shi SD. Figure 2 shows the killing of 1〇6 to 1〇Lactobacillus acidophilus PM-A0002 strain, Lactobacillus gasseri PM-A0005 strain, Lactobacillus salivarum by heat. Lactobacillus salivarius subsp. salicinius) PM-A0006 strain, Yorkshire 201210509 Lactobacillus johnsonii PM-A0009 strain or Lactobacillus acidophilus PM-A0013 strain and 105 to 1〇7 human dendritic cells (dentritic Cell) was co-cultured for 48 hours, cell supernatant was collected, and the amount of interleukin (IL-12) in the supernatant was detected by enzyme immunoassay. Among them, Lactobacillus casei BCRC12249 was used as a negative control group, PHA was a positive control group, and the interleukin (IL_12) stimulated concentration was detected. The results showed that the experimental group significantly stimulated the secretion of intercellular white pigment (IL-12) from human dendritic cells and the negative control group was significantly different. Table 4 shows the secretion of intercellular white pigment (IL-12) in the name of intercellular white pigment (IL_12) strains (pg/ml) by five heat-killing anti-allergic strains and dendritic cells, respectively. Lactobacillus PM-A0002 15019±569 Lactobacillus lactis PM-A0005 19222士212 Salivary lactic acid bacteria PM-A0006 18625士365 Lactobacillus johnsonii PM-A0009 18291士39 Lactobacillus acidophilus PM-A0013 17836±168 Negative control Group (L. casei BCRC 12249, 80±15 positive control group 13786±341 Table 4 Example 4: Anti-allergic lactic acid bacteria resistant to gastric acid bile salt test. Examination of five anti-allergic lactic acid strains, Lactobacillus acidophilus pM_A〇 Can the 〇〇2 strain, Lactobacillus calyceii PM-A0005 strain, Lactobacillus salivarius pM_A〇〇〇6 strain, Lactobacillus johnsonii PM-A0009 strain or Lactobacillus acidophilus PM_A〇〇13 have the ability to pass the test of gastric acid bile salt Smoothly exert its anti-allergic function in the intestines. The test procedure is as follows: 1. Activate five anti-allergic lactic acid bacteria for 3 days. 2. Calculate the original bacteria number by taking 1 mL of bacterial liquid, and centrifuge the remaining lactic acid bacteria at 5 〇〇g. 12 201210509 : Knowing to add deionized water to clean lactic acid bacteria 2-3 times. Live fine, clean the water 2 butterfly 'calculation save 5 · After the centrifugation, the precipitate will be centrifuged to contain 37 cells, and the number of live cells will be 4 hours. 7. The growth rate of acid g' is calculated as the lactic acid bacteria in the sample of gastric biliary tract in the presence of gastric acid and bile salts, and the growth of the strain is analyzed by the analysis in Table 5 and Figure 3, the third After the activation of the medium, the total bacterial sensitivity of the acid lactic acid bacteria decreased significantly; the adjusted solution and the specific: =6, ^^ 趟Hi and the tolerance to gastric acid, but the strain passed through the gallbladder ^处=, Laiwu strain has a slight decline, but it is still tolerant to bile salts. Note that the five strains of lactic acid can pass the digestive system of the human body. The environment S is a hydrochloric acid and anti-(5) value of 2.5. Allergy lactic acid bacteria mixed test

二=改,躺急劇下降,—二 13 201210509 i酸乳吃j__PM^0013j 1.78X109 1.83X109! l,86xl〇j l,73xl〇9 表5 耐膽鹽的忐力結果與分析整理於表6及第3圖所示,表6 為以1.5%的膽汁與抗過敏乳酸菌混合測驗其耐膽鹽能力。 菌株名稱 原始菌 數 1.5%bile-lhr 1.5%bile-2hr 1.5%bile-3hr 1.5%bile-4hr 嗜酸乳桿菌 PM-A0002 8.2〇xl〇8 4.3〇xl〇6 1.5〇xl〇6 5.45x10s 4.4〇xl05 加式乳酸桿菌 PM-A0005 2.65xl〇9 5.8〇xl〇4 5.55xl04 2.4〇xl04 1.89xl04 唾液乳酸桿菌 PM-A0006 2.55xl〇9 1.45x10s 9.2〇xl07 1.02xl08 8.3〇xl07 約氏乳酸桿菌 PM-A0009 6.87xl〇8 8.65xl〇7 1.13xl08 5.7〇xl〇7 8.3〇xl06 嗜酸乳桿菌 PM-A0013 1.78xl〇9 6.72x10s 5.73x10s 8.0〇xl〇6 3.00xl05 表6 貫例5 .抗過敏乳酸菌對人類腸道表皮細胞(CaC〇_2)的吸 附能力試驗。 在活體外採用已分化的細胞株分析五株抗過敏乳酸菌菌 株吸附人_道表皮細胞(CaCo_2)的能力。先由人類腸道表皮 細胞(CaCo-2)單層細胞株於蓋玻片上生長至單層細胞後,置入 多孔細胞培養盤中。然後將細胞:乳酸菌之比例為1 : 200, 共同培,/-3小時,以Ixpbs清洗及利用曱醇固定細胞及剩 餘之附^菌數後,以IxPBS清洗及利用甲醇固定後細胞及剩 餘之附著菌數後,進行格蘭氏染色並確定所附著之菌數。參考 Jacobsen等學者(1999)之分析方法,在1〇〇〇倍顯微鏡下計數 201210509 20個視野,當每個視野的平均菌數少於4〇時,判定為不附著 (nonadhesive);當每個視野的平均菌數介於41至1〇〇時判 定為附著(adhesive);當每個視野的平均菌數大於1〇〇時,判 定為強烈附著(strongly adhesive) 〇 數據之統5*1*分析以Mean ± SD表示之。平均來說,取四十 五個視野之計算值.其結果整理於表7及第4圖所示。第4圖 顯不依據Jacobsen等學者(1999)之分析方法,當每個視野的平 均菌數少於40時,判定為不附著(n〇nadhesive);當每個視野 的平均菌數介於41至100時,判定為附著(adhesive);當每個 視野的平均菌數大於100日寺,判定為強烈附著(伽峨 adhesive)。顯示嗜酸乳桿菌(Lact〇badiius acid〇philUS)PM-A0002 菌株、加氏乳酸桿菌(Lact〇badllus gaSSeri)PM-A_5 菌株、唾液乳酸桿菌(Lact〇badllussaiivarius —sp· SaliciniUS)PM-A0006 菌株、約氏乳酸桿菌 j:hns〇nii)PM-A0009菌株等四株抗過敏菌株均判定「強烈附 著」而嗜酸乳桿菌(Lactobacillus acidophilus)PM-A0013 菌株則 判定為附著。表7為五株抗過敏乳酸菌對人類腸道表皮細胞 (CaCo-2)細胞株之吸附能力試驗: 菌株名 嗜酸乳桿菌 PM-A0002 MeansiSD --*--- 115.4±4.4 加式乳酸桿菌 PM-A0005 100.1 士 2.6 唾液乳酸桿菌 PM-A0006 108.3 土 1.4 約氏乳酸桿菌 PM-A0009 208.3 土 22.1 嗜酸乳桿菌 PM-A0013 02.8±5.0 表7 實例6 :以抗過敏乳酸菌作為補充飼料所產生治療或舒緩 過敏性氣喘的效果’藉由以餵食唾液乳酸桿菌ρμ_α〇〇〇6給即 蛋白(ovalbumin; OVA)致氣喘小白鼠為例藉由如下之實驗進行 15 201210509 過敏改善評估。 A.實驗設計 實驗動物 細^用趣义小鼠,6_8週大’雌鼠,對照組與實驗組每· =4隻。選用常用的祖阶雌鼠,8週大,顧食六週,每 數^14隻。自台大動物中心購進sPF六週大的BALB/c 昧’母隻小鼠分別铜養於不鏽鋼籠中,室溫控制於22±2〇c, =循環咖各為12小時(早上六點亮,科六點暗),自由 飲水及飼料,小鼠八週大時以體重隨機分組,開始以管银 方式給予受測乳酸離趟^故奶舰咖同時進行致敏。 2.建立呼吸道發炎動物模式 既双舣穸驟間述如下··實驗開始第2天以5〇吨卵白蛋 $ (OVA)與佐劑Aklm 4mg腹腔注射至小鼠體内,於實驗第 —、30、44天再以25吨之印白蛋白(〇VA)與4mgAhm^ f注射老鼠。致敏後,在實驗第54、55天,將小鼠麻醉,以 鼻腔内(mtra-naSal,i.n.)滴人100路印白蛋白(〇v 發呼吸道發炎反應。 济 3.實驗流^如第5圖所示,抗過敏乳酸g改善過敏實驗的設計 流程,管餵抗過敏乳酸菌之階段分為四期:第一期為〇〜22 天;第二期為23〜36天;第三期為37〜5〇天;第四期為Μ〜幻 天。其間以腹腔注射卵蛋白(0VA)致敏小鼠,分四次致敏, 第=次為開始管歉第2天;第二次為開始管飯之第16天; 第三次為開始管餒之第30天;第四次為開始管傲之第料天: 腹腔注射印蛋白(OVA)致敏小鼠之隔週皆會抽血檢查小鼠之 IgE在體内含量之變化。於犧牲小鼠前4天(第%天)以鼻黏 膜吸入之方式練小鼠連續2天後,侧小鼠之肺呼吸&力 之反應’隔天犧牲小鼠進行其他生化值的檢測。 Β·實驗方法 201210509 i.動物犧牲和實驗材料收集與分析 a.血清樣品的收集 =驗進行第〇、23、37、51 Λ及犧牲時對小鼠進行以 __bital)收集血樣。割、鼠麻醉後,迅速以微 里毛、..田官自眼窩靜脈竇採血,約取2〇〇_25〇吣血液,4。〇靜 置2 — 4小時後,以12000 rpm轉速離心20分鐘,收集血 清’於-80°C保存。 八 b.測定印蛋白(OVA)專一性抗體的酵素免疫分析(ELISA) 將 〇.5mg 抗原溶於 lOOgL carb〇nate coating buffer ((λ 1 ΜTwo = change, lay down sharply, - two 13 201210509 i yogurt to eat j__PM^0013j 1.78X109 1.83X109! l,86xl〇jl, 73xl〇9 Table 5 The results and analysis of the gallbladder salt in Table 6 and As shown in Figure 3, Table 6 tests the bile salt tolerance of 1.5% bile mixed with anti-allergic lactic acid bacteria. Strain name Original bacteria number 1.5%bile-lhr 1.5%bile-2hr 1.5%bile-3hr 1.5%bile-4hr Lactobacillus acidophilus PM-A0002 8.2〇xl〇8 4.3〇xl〇6 1.5〇xl〇6 5.45x10s 4.4 〇xl05 Plus Lactobacillus PM-A0005 2.65xl〇9 5.8〇xl〇4 5.55xl04 2.4〇xl04 1.89xl04 Lactobacillus saliva PM-A0006 2.55xl〇9 1.45x10s 9.2〇xl07 1.02xl08 8.3〇xl07 Lactobacillus faecalis PM -A0009 6.87xl〇8 8.65xl〇7 1.13xl08 5.7〇xl〇7 8.3〇xl06 Lactobacillus acidophilus PM-A0013 1.78xl〇9 6.72x10s 5.73x10s 8.0〇xl〇6 3.00xl05 Table 6 Example 5. Anti-allergy The adsorption capacity of lactic acid bacteria on human intestinal epithelial cells (CaC〇_2). Five different anti-allergic lactic acid bacteria strains were used to analyze the ability of human anti-allergic lactic acid bacteria to adsorb human-tall epidermal cells (CaCo 2 ) in vitro. Human intestinal epithelial cells (CaCo-2) monolayers were first grown on coverslips and plated into monolayer cells and placed in a multi-well culture dish. Then, the ratio of cells: lactic acid bacteria was 1:200, co-cultured, /-3 hours, washed with Ixpbs and fixed with sterol and the remaining number of bacteria, washed with IxPBS and fixed with methanol and remaining After adhering the number of bacteria, gram staining was performed and the number of attached bacteria was determined. Referring to the analysis method of Jacobsen et al. (1999), 20 fields of 201210509 were counted under a 1× microscope, and when the average number of bacteria per field of view was less than 4〇, it was judged as nonadhesive; When the average number of bacteria in the field of view is between 41 and 1 判定, it is judged as adherence; when the average number of bacteria per field of view is greater than 1 ,, it is judged to be strongly adhesive 〇 data of 5*1* The analysis is expressed in Mean ± SD. On average, the calculated values of forty-five fields of view are taken. The results are summarized in Tables 7 and 4. Figure 4 shows that according to the analysis method of Jacobsen et al. (1999), when the average number of bacteria per field of view is less than 40, it is judged as not attached (n〇nadhesive); when the average number of bacteria per field of view is 41 When it was 100, it was judged to be adherent; when the average number of bacteria per field of view was greater than 100 days, it was judged to be strongly attached (glyphs adhesive). Lactabidais acid〇philUS PM-A0002 strain, Lactobacillus calvus gaSSeri PM-A_5 strain, Lactobacillus salivarius (sp. SaliciniUS) PM-A0006 strain, Four anti-allergic strains such as Lactobacillus johnsonii j:hns〇nii) PM-A0009 strain were judged to be "strongly attached" and Lactobacillus acidophilus PM-A0013 strain was judged to be attached. Table 7 shows the adsorption capacity of five anti-allergic lactic acid bacteria on human intestinal epithelial cells (CaCo-2) cell line: strain name Lactobacillus acidophilus PM-A0002 MeansiSD --*--- 115.4±4.4 Lactobacillus lactis PM -A0005 100.1士2.6 Lactobacillus salivarius PM-A0006 108.3 Soil 1.4 Lactobacillus johnsonii PM-A0009 208.3 Soil 22.1 Lactobacillus acidophilus PM-A0013 02.8±5.0 Table 7 Example 6: Treatment with anti-allergic lactic acid bacteria as supplementary feed or The effect of soothing allergic asthma was evaluated by the following experiment using the following experiment with the administration of Lactobacillus sp. Lactobacillus ρμ_α〇〇〇6 to the protein (ovalbumin; OVA)-induced asthmatic mice. A. Experimental design Experimental animals Fine mice were used, 6-8 weeks old female rats, control group and experimental group each = 4 rats. The commonly used female ancestors were selected, 8 weeks old, and eat for six weeks, each number ^14. Purchased sPF six-week-old BALB/c 昧 'mother mice from the National Taiwan University Animal Center were housed in stainless steel cages at room temperature, controlled at 22±2〇c, and cycled coffee for 12 hours (shine in the morning) , 6 points dark, free drinking water and feed, the mice were randomly divided into groups at the age of eight weeks, began to give the test lactic acid by tube silver. 2. Establish an animal model of respiratory tract inflammation. The two-step procedure is as follows: · On the second day of the experiment, 5 ton of egg white egg (OVA) and adjuvant Aklm 4 mg were intraperitoneally injected into the mouse, in the experiment - In 30 and 44 days, mice were injected with 25 tons of albumin (〇VA) and 4 mg of Ahm^f. After sensitization, on the 54th and 55th day of the experiment, the mice were anesthetized, and intramary (mtra-naSal, in) drops of 100-way albumin (〇v hair respiratory inflammatory reaction. Ji 3. Experimental flow ^ as the first In the figure 5, the anti-allergic lactic acid g improves the design process of the allergy experiment. The stage of feeding the anti-allergic lactic acid bacteria is divided into four phases: the first phase is 〇~22 days; the second phase is 23~36 days; the third phase is 37~5〇天; the fourth period is Μ~幻天. In the meantime, mice were sensitized by intraperitoneal injection of egg protein (0VA), which was sensitized four times, the second time was the first day of apology; the second time was The 16th day of the start of the tube; the third day is the 30th day of the start of the tube; the fourth time is the first day of the tube: the intraperitoneal injection of the albumin (OVA) sensitized mice will be blood-tested every other week. Changes in the content of IgE in mice. In the first 4 days (day%) of the sacrificial mice, the mice were trained by nasal mucosa inhalation for 2 consecutive days, and the lungs of the mice were reacted with the force response. Sacrificial mice were tested for other biochemical values. Β·Experimental method 201210509 i. Animal sacrifice and experimental material collection and analysis a. Collection of serum samples = test When 23,37,51 Λ mice were sacrificed and blood samples were collected __bital). After cutting and anaesthetizing the rats, the blood is quickly collected from the orbital sinus, and about 2 〇〇25 blood is taken. The cells were allowed to stand for 2 to 4 hours, centrifuged at 12,000 rpm for 20 minutes, and the serum was collected and stored at -80 °C. VIII b. Determination of the protein (OVA)-specific antibody by enzyme immunoassay (ELISA) Dissolve 〇.5mg of antigen in lOOgL carb〇nate coating buffer ((λ 1 Μ

NaHC〇3)加入微量培養盤於4〇c靜置過夜。第2天以含有 0.05% Tween 20之IX PBS緩衝液清洗微量培養盤。然後以 blocking solution (含有 1% BSA 之 IX PBS 緩衝液)進行 blocking兩小時以上’清洗3次後,接著加入ι〇〇μ]^待測樣 本反應於4°C靜置過夜,清洗4次後,加入lOOpL抗小鼠igE 抗體於室溫反應一至兩小時,再清洗5次。加入1〇〇 pL經適 當稀釋之 avidin-HRP (avidin-horseradish peroxidase conjugated) 反應一小時,清洗6次,最後加入100 μ]: ABTS ( 2.2,-Azino-bis-3- Ethylbenzthiazoline -6-Sulfonic Acid)受質溶液於室溫呈 色約30分鐘後,以100 pL之5% SDS終止反應,並以吸光值 讀取機(microplate reader)讀取吸光值。測定結果以酵素免疫 分析(ELISA) unit方式表示如下: ELISA. Ulllt _ (Agample Ablank) / (Apositive control — Ablank)NaHC〇3) was added to a microplate and allowed to stand overnight at 4 °C. On the second day, the microplate was washed with IX PBS buffer containing 0.05% Tween 20. Then block for more than two hours with blocking solution (1% BSA in IX PBS buffer), after 3 washes, then add ι〇〇μ^^ The sample to be tested is allowed to stand at 4 ° C overnight, after 4 washes. Add lOOpL anti-mouse igE antibody to react at room temperature for one to two hours, and then wash 5 times. Add 1 〇〇pL to the appropriately diluted avidin-HRP (avidin-horseradish peroxidase conjugated) for one hour, wash 6 times, and finally add 100 μ]: ABTS ( 2.2,-Azino-bis-3- Ethylbenzthiazoline -6-Sulfonic Acid After the substrate was colored at room temperature for about 30 minutes, the reaction was terminated with 100 pL of 5% SDS, and the absorbance was read with a microplate reader. The results are expressed as follows by enzyme immunoassay (ELISA) unit: ELISA. Ulllt _ (Agample Ablank) / (Apositive control — Ablank)

c.呼吸道過度反應(airway hyperresponsiveness,AHR)測定 為研究口服抗過敏乳酸菌是否能減緩致敏小鼠之過敏反 應,在兩次氣管内過敏原刺激後’隔天接受呼吸道阻力的測 試。測試系統為 Buxco system (Biosystem XA,Buxco Electronics Inc. Sharon, CT,USA)。利用系統中的 transducer (differential pressure transducer,Buxco)及 preamplifier (MAX 17 201210509 II,Buxco)收集小鼠呼吸道變化的訊息而計算出值。 Penh 值的計算方式為 pause x PIF/PEF ; Pause =听 _ Tr) / Tr, (PIF : peak inspiratory flow ; PEF : peak expiratory flow ; Te : expiratory time ; Tr : relaxation time)。小鼠在意識清醒狀態下 置於 whole body plethysmograph chamber 中,以超音波震盪氣 化normal saline導入chamber三分鐘,之後紀錄小鼠三分鐘 内每分鐘平均肺呼吸阻力值Penh,再以漸增濃度之c. Airway hyperresponsiveness (AHR) assay To investigate whether oral antiallergic lactic acid bacteria can alleviate allergic reactions in sensitized mice, and receive airway resistance tests the next day after two intratracheal allergen stimuli. The test system was Buxco system (Biosystem XA, Buxco Electronics Inc. Sharon, CT, USA). Values were calculated using a transducer (differential pressure transducer, Buxco) and preamplifier (MAX 17 201210509 II, Buxco) to collect information on changes in respiratory tract in mice. The Penh value is calculated as pause x PIF/PEF ; Pause = Listen _ Tr) / Tr, (PIF : peak inspiratory flow ; PEF : peak expiratory flow ; Te : expiratory time ; Tr : relaxation time). The mice were placed in the whole body plethysmograph chamber under conscious state, and the normal saline was introduced into the chamber for three minutes by ultrasonic vibration. Then, the average lung respiratory resistance value Penh was recorded for three minutes in the mouse, and then the concentration was increased.

Methacholine(6.25、12·5、25、50mg/mL)噴霧化給予小鼠刺 激,各濃度皆在刺激三分鐘後,再記錄三分鐘之呼吸道生理變 化。記錄三分鐘内各分鐘平均penh值。 d. 肺沖洗液及肺部細胞分析 測試完肺呼吸阻力隔天,小鼠進行犧牲,剪開頸部皮肉使 氣管露出,以靜脈置留管插入氣管,第一次先以i I無菌 HBSS buffer沖洗肺部,第二及第三次則以含有2% BSA之 HBSSbufFeM中洗肺部’首次取得之肺沖洗液經15〇〇rpm離 心5分鐘後,分離上清液保存於_8(rc待後續分析。細胞部 为則併入後兩次肺沖洗液中,以15〇〇 jpm離心$分鐘,棄置 上清液後並將細胞以lmL含有2% BSA之HBSS buffer'縣 浮,並以trypan blue染色計數,取約! χ 1〇5之細胞以離二 機(Cyt〇Spin) 500,離心3分鐘製作細胞抹片,待其自然風 乾後,依序以LhiA及LiuB染色,以少量阿拉伯膠封片, 使用油鏡(lGGG X)判讀至少五個視野之細胞或總數3〇〇個 以上之細胞,計算其中淋巴球及多核球比例。 e. 脾臟細胞培養 無菌條件下,打開小氣腹腔取出脾臟置於已加入3此 2Gmmpetridish内,以無菌針筒 磨碎,使其中淋巴細胞釋出,細胞懸浮液吸入15祉離 靜置5分知後’取上清液以i5QQrpm離心5分鐘,吸除上 18 201210509 清液後,加入1 mL RBC lysis buffer,靜置1分鐘使紅血球溶 解,加入5 mL HBSS buffer,以1500 φΐη離心5分鐘’吸 除上清液;以HBSS buffer重複洗兩次後,再加入5 mL含 5% FBS 之 RPMI-1640 complete medium 使細胞懸浮。以 trypan blue染色法計算細胞總數,調整細胞數至1 X 1〇7 cells/mL medium。取細胞液 0.5 mL 加入 48-well plate 中,再 加入等體積培養液、含裂殖素或卵蛋白(OVA)之培養液,使細 胞最終濃度為5 x 1〇6 cells/mL medium。置於怪溫培養箱 37°C、5%C〇2培養48小時’收取上清液保存於待曰 後分析其中各細胞激素分泌量。 f.細胞激素的測定 脾臟細胞分泌細胞激素的含量以三明治型酵素免疫分析 法(ELISA)來測定。簡述如下:先將抗細胞激素抗體以NaHC〇3 緩衝液(pH 9.6)稀釋後加入96孔微量培養盤於4°C靜置過 夜。第二天將培養盤清洗3次後,以含1%BSA之PBS在室 溫下反應至少1小時進行填塞(blocking)。加入待測樣本後可 於37。(:反應2小時或置於4°C反應過夜。清洗4次後加入 以1% BSA-PBS緩衝液稀釋之bi〇tin_c〇njugated抗細胞激素 抗體於室溫反應1小時’清洗5次,接著加人卿㈣胞_ conjugated peroxidase再反應丨小時。最後在清洗後,每孔加 入1〇〇 μί的酵素受質溶液ΤΜβ substrate (Tetmmethylbenzidine substrate) ’ 於室溫避光反應約 2〇 分鐘。 以 rmcroplate autoreader 讀取波長 450 nm 的 2_統計方法 &m ㈣ΐΐίΐΤ均值4鮮誤絲示(MeanS±S_。各 Ρ<=分析,P<aG5視為有顯著差異(*, Ρ 0·05,,ρ<0·001)。另外將 p<〇1 實驗結果分析: β左兵 19 201210509 ^測定白(OVA)專-性抗體的酵素免疫分娜lisa)結 呆 π >卵蛋白(OVA)特異性抗體效價部分,餵食 A0006乳酸菌的對照組,卵蛋白(〇VA)致敏小鼠血清中的 ^蛋白(OVA:)特異性1成抗體有減少的趨勢結果於表8,圖 示於第6圖。表8顯示印蛋白(〇VA)專一性抗體姊測定結果 組別 A 1 A 飞? A v aiuc—J 對照組 實驗組 IgE 0.66±0.05 0.44±0.03(P=0.06)# ELISA unit = #:P<0.1 sample A blank) ! (A positive control ~ A blank) 表8 B.呼吸道過度反應(airway hyperresponsiveness,AHR)測 定結果 肺呼吸阻力部分,相對於對照組,餵食PM-A0006乳酸 菌在高濃度乙醯丑曱基膽素(Methacholine)刺激下顯著減低 小鼠Penh值。結果於表9,圖示於第7圖。表9顯示呼吸道 過度反應測定結果(Means±SEMs, N=14, P value=P) 組別(Mch : mg/mL) 對照組(Penh) 實验組(Penh) 0 1.41±0.05 1.44 士 0.08(P=0.86) 6.25 1.50±0.11 1.35±0.11(P=0.62) 12.5 2.59 土 0.24 1.94±0.20(P=0.28) 25 4.38±0.47 1.95±0.12(P=〇.〇8)# 50 5.10±0.32 2.63±0.13(P=0.〇〇2)* 20 201210509Methacholine (6.25, 12·5, 25, 50 mg/mL) was spray-administered to the mice, and each concentration was stimulated for three minutes and three minutes of respiratory physiological changes were recorded. Record the average penh value for each minute in three minutes. d. Lung lavage fluid and lung cell analysis test lung respiratory resistance test the next day, the mouse sacrificed, cut the neck and flesh to expose the trachea, the venous catheter is inserted into the trachea, the first time I i sterile HBSS buffer Rinse the lungs, and in the second and third time, wash the lungs with HBSSbufFeM containing 2% BSA. The first obtained lung washing solution was centrifuged at 15 rpm for 5 minutes, and the supernatant was separated and stored at _8 (rc Subsequent analysis. The cell part was then inoculated into two lung lavage fluids, centrifuged at 15 〇〇 jpm for $ minutes, the supernatant was discarded, and the cells were floated with 1 mL of HBSS buffer containing 2% BSA, and trypan Blue staining count, take about! χ 1〇5 cells to centrifuge two centrifugation (Cyt〇Spin) 500, centrifuge for 3 minutes to make cell smear, after it is naturally dried, stained with LhiA and LiuB in sequence, with a small amount of gum arabic Capsules, use oil mirror (lGGG X) to read at least five fields of view cells or a total of more than 3 cells, calculate the proportion of lymphocytes and multinuclear spheres. e. Spleen cells culture under sterile conditions, open the small gas abdominal cavity to remove the spleen Placed in 3 this 2Gmmpetridish has been added, no The syringe was ground, and the lymphocytes were released. The cell suspension was inhaled for 15 minutes and then left to stand for 5 minutes. The supernatant was centrifuged at i5QQ rpm for 5 minutes. After removing the supernatant from 201210509, add 1 mL of RBC lysis. Buffer, let stand for 1 minute to dissolve red blood cells, add 5 mL HBSS buffer, centrifuge at 1500 φΐη for 5 minutes to 'absorb the supernatant; repeat twice with HBSS buffer, then add 5 mL of RPMI-1640 with 5% FBS Complete medium to suspend the cells. Calculate the total number of cells by trypan blue staining, adjust the number of cells to 1 X 1〇7 cells/mL medium, add 0.5 mL of cell solution to 48-well plate, add equal volume of culture medium, and split. The culture medium of the hormone or egg protein (OVA) is allowed to have a final concentration of 5 x 1 〇 6 cells/mL medium. The culture supernatant is placed in a strange temperature incubator at 37 ° C and 5% C 〇 2 for 48 hours. After storage, the amount of cytokine secretion in each cell was analyzed. f. Determination of cytokine The content of cytokines secreted by spleen cells was determined by sandwich enzyme immunoassay (ELISA). Briefly described as follows: NaHC〇3 buffer (pH 9.6 After dilution, a 96-well microplate was added and allowed to stand overnight at 4 ° C. The plate was washed 3 times the next day, and then blocked by reacting with PBS containing 1% BSA at room temperature for at least 1 hour. After adding the sample to be tested, it can be 37. (: reaction for 2 hours or at 4 ° C for overnight. After washing 4 times, add bi〇tin_c〇njugated anti-cytokine antibody diluted in 1% BSA-PBS buffer for 1 hour at room temperature 'wash 5 times, then Add qing (4) _ conjugated peroxidase and then react for 丨 hours. Finally, after washing, add 1 μμ of enzyme substrate Tβ substrate (Tetmmethylbenzidine substrate) to each well for about 2 〇 minutes at room temperature. Autoreader reads the 2_statistical method &m (four) ΐΐίΐΤ mean value 4 of the wavelength 450 nm (MeanS±S_. Each Ρ<= analysis, P<aG5 is considered to be significantly different (*, Ρ 0·05,, ρ&lt ;0·001). Further analysis of p<〇1 experimental results: β左兵19 201210509 ^Determination of white (OVA)-specific antibody enzyme immunoassay lisa) π > egg protein (OVA) specificity In the antibody titer portion, the control group of A0006 lactic acid bacteria, the protein (OVA:) specific antibody in the serum of ovarian (〇VA) sensitized mice showed a trend of decreasing. The results are shown in Table 8. Figure 8. Table 8 shows the specific antibody 姊 determination of the printed protein (〇VA) Results group A 1 A fly? A v aiuc-J control group IgE 0.66±0.05 0.44±0.03 (P=0.06)# ELISA unit = #:P<0.1 sample A blank) ! (A positive control ~ A blank Table 8 B. Airway hyperresponsiveness (AHR) As a result of lung respiratory resistance, compared with the control group, the feeding of PM-A0006 lactic acid bacteria significantly reduced the mice under the stimulation of high concentration of Methcholine. Penh value. The results are shown in Table 9, which is shown in Figure 7. Table 9 shows the results of airway hyperreactivity (Means ± SEMs, N = 14, P value = P) group (Mch : mg / mL) control group (Penh) experimental group (Penh) 0 1.41 ± 0.05 1.44 ± 0.08 ( P=0.86) 6.25 1.50±0.11 1.35±0.11 (P=0.62) 12.5 2.59 Soil 0.24 1.94±0.20 (P=0.28) 25 4.38±0.47 1.95±0.12 (P=〇.〇8)# 50 5.10±0.32 2.63± 0.13 (P=0.〇〇2)* 20 201210509

Mch=Methacholne 配製濃度Mch=Methacholne formulated concentration

Penh=pause x PEF/PEF ; Pause=(Te - Tr) / Tr, (PIF : peak inspiratory flow; PEF : peak expiratory flow; Te : expiratory time; Tr : relaxation time) * : p < 0.05 # :P<0.1___ 表9 C.肺沖洗液及肺部細胞分析結果 肺沖洗液中細胞組成部分,相對於對照組,餵食PM-A0006 乳酸菌的實驗組有顯著較低的嗜伊紅白血球(eosinophil)浸潤 比例。結果總結於表10,圖示於第8圖。表10顯示肺沖洗液 組別 對照組(%) 實驗組(%) eosinophil 27.5±1·37 17.1±1.66(Ρ=0.02)* %=In percentage 0/〇 * : P<0.05 表10 D.肺沖洗液細胞激素分析結果 相對於對照組,餵食PM-A0006乳酸菌的實驗組可顯著 降低肺沖洗中e〇taxin分泌量且pGE2&有減少之趨勢。結果 總結於表11,圖示於圖9及第1〇圖。表η顯示肺沖洗細胞 激[^分析結果(Means±Sg^[s. N=14, P value=P) 級別 :_ 對照組 χ、 Α^,Α ν χ / 實驗組 38.8±3.00 22.7 士 1.54(Ρ=0.02)* pge2 ---£__ 8.1±1.〇4 3.82±0.41(Ρ=0.08)# * : Ρ<0.05 21 201210509 表11 E.脾臟細胞培養之上清液細胞激素分析結果 脾臟細胞經ConA或卵蛋白(OVA)刺激培養48小時♦ 後,在ConA刺激下,餵食PM-A0006乳酸菌的實驗組之脾·' 臟細胞分泌的IFN-γ顯著高於對照組。結杲蛐紝於裊丨2,圖 11 ® ^ 12 同刺激物質對脾臟細胞之細胞激素分泌之影響(Means±SEMs, N=14, P value=P) 組別 對照組 實驗組 ConA 5185士558 9748±966(Ρ=〇·〇5、* * : PO.05 表12 綜合上述’本發明電化學免疫檢驗試#係_免疫反應有 效地克服電化學法檢測之干祕問題,提高檢繼感度。另 外,本發明可提供-單步驟快速檢驗試片與定量之檢測,又, 更結合生物技術與電子製秘術生產低成本 物科技檢驗試片。 本發明之食品組合物,含有以摘述之任意—種或一種以 上菌株所組合而成之各種組合物,例如 乳製飲品乳粉、茶或咖啡轉,日'礼路 存於組合物中/ #㈣株可以活核死菌的樣態 ㈣揮抗過敏的效果除了要找出具有特定功 ϊίί= 魏财人體胃咖㈣環境外, ^要月•對小腸黏膜表皮細胞具有良好 同時增強™ 抗過敏乳酸菌可 匕lh2過盛的過敏反應。本發明的一個 22 201210509 目標就是_朝向達成這些希求歧少提供大眾在過敏 上除類固醇或是抗組織氨的的新選擇,本發明找 := 作用且有益健義抗過敏乳_來作為過敏治療的H副 以上所述係藉由實施例說明本發明之特點,其目的在使熟 技術者能暸解本發明之内容並據以實施,而非限定本發日月'之= 利範圍,故,凡其他未脫離本發明所揭示之精神所完^之 修飾或修改,仍應包含在以下所述之申請專利範圍中。夕 【圖式簡單說明】 第1圖顯示,當分別以ίο6至108個cfil嗜酸乳桿菌 (Lactobacillus addophilus)PM-A0002 菌株、加氏乳酸桿菌 (Lactobacillus gasseri)PM-A0005 菌株、唾液乳酸桿菌 (Lactobacillus salivarius subsp. salicinius)PM-A0006 菌株、約氏 乳酸桿菌(Lactobacillus johnsonii)PM-A0009菌株或嗜酸乳桿菌 (Lactobacillus acidophilus)PM-A0013 菌株與 1〇5至 1()7個人類周 邊也液白血球(PBMC)共同培養48小時,收取細胞上清液,'以 酵素免疫分析法偵測干擾素γ (IFN-gamma)在上清液中的含 里。其中以無抗過敏功能乳酸菌(Lact〇bacillus casei BCRC12249)為負控制組,PHA為正控制組,偵測干擾素γ受 刺激濃度。結果顯示試驗組可以顯著的刺激人類周邊血液白血 球(PBMC)分泌干擾素γ與負控制組有顯著性差異。 第2圖顯不’當分別以熱殺死1〇6至].〇8個cfU嗜酸乳桿 菌(Lactobacillus acidophilus)PM-A0002 菌株、加氏乳酸桿菌 (Lactobacillus gasseri)PM-A0005 菌株、唾液乳酸桿菌 (Lactobacillus salivarius subsp. salicinius)PM-A0006 菌株、約氏 乳酸桿菌(Lactobacillus johnsonii)PM-A0009菌株或嗜酸乳桿菌 (Lactobacillus acidophilus)PM-A0013 菌株與 1〇5 至 1〇7個人類樹 狀細胞(dentritic cell)共同培養48小時,收取細胞上清液,以 酵素免疫分析法偵測細胞間白素IL-12在上清液中的含量。其 23 201210509 中以無抗過敏功此乳酸菌(Lact〇baciiius casei BCRC12249)為 =控制組’ PHA為正控制組,偵測細胞間白素(IL_12)受刺激 濃度。結細示試驗組可賴著賴激人娜 . 間白素(IW2)與貞㈣組抽㈣差異。 力 /第^圖顯示’結_示市售抗過敏乳酸菌在培養基的活化 後’總菌數經由酸性緩衝溶液及膽鹽處理,菌數明顯下降許 多;調節過敏之專利寄存乳酸菌株在培養基活化後,將菌株處 ,酸性緩衝溶液及膽鹽,PM_A〇〇〇6、pM_A〇()()9、pM_AQQi3 菌數並不受胃酸膽鹼改變影響而急劇下降,pM_A〇〇〇2及 ΡΜ·^0005雖然不受胃酸而影響菌數證明對胃酸具有耐受性, 但將菌株經由膽鹽處理時,雖然菌株有些許的下降,但對膽鹽 仍有耐受性,証明抗過敏之此五株乳酸菌株可以通過人體消化 糸統嚴格環境的考驗。 第4圖顯示’依據jac〇bsen等學者(1999)之分析方法當 每,視野的平均g數少於40時,判定為獨著(n_dhesive); 當每個視野的平均菌數介於41至1〇〇時,判定為附著 (adhesive);當每個視野的平均菌數大於1〇〇時,判定為強烈 附著(strongly adhesive)。顯示嗜酸乳桿菌(Lact〇baciUus acidophilus)PM-A0002 菌株、加氏乳酸桿菌(Lact〇baciUus gasseri)PM-A0005 菌株、唾液乳酸桿菌(Lact〇baciUussalivarius subsp. salicimus)PM-A0006 菌株、約氏乳酸桿菌(Lactobacillus johnsonii)PM-A0009菌株等四株抗過敏菌株均判定「強烈附 著」而嗜酸乳桿菌(Lactobacillus acidophilus)P]V[-A0013 菌株則 判定為附著。 ' 第5圖顯示,抗過敏乳酸菌改善過敏實驗的設計流程,管 餵抗過敏乳酸菌之階段分為四期:第一期為〇〜22天;第二期 為23〜36天;第三期為37〜50天;第四期為51〜53天。其間以 腹腔注射卵蛋白(OVA)致敏小鼠,分四次致敏,第一次為開始 24 201210509 cm: 6天;第三次為開始 =之,3〇天,第四:人為開始管饒之第44天。腹腔注射印蛋 白(ovalbumm ; 〇VA)致敏小鼠之隔週皆會括血 4 54 =之方式致敏小鼠連續2天後,_小鼠之肺呼吸阻力之反 應’隔天犧牲小鼠進行其他生化值的檢測。 =6圖顯示,為小白鼠補充唾液乳酸桿g ρΜ_Α〇_乳酸 蛋白致敏的小白鼠血清中卵蛋白(〇VA)特異性抗 ^著餵食鮮增加,彡卩蛋白(0VA)致敏小鼠血清 中的★印蛋白(OVA)特異性IgE抗體有減少的趨勢。 ^ 7圖顯示,為小白鼠補充唾液乳酸桿g pM_A〇〇〇6乳酸 株= 夺’以,蛋白致敏的小白鼠肺呼吸阻力部分,相對於對照 =’ ^可在高濃度乙醯丑甲基膽素(methach〇line)刺激下 低小鼠Penh值。 # = 8圖顯示’為小白鼠補充唾液乳酸桿菌pM_A〇⑻6乳酸 蛋白致敏的小白鼠肺沖洗液中細胞組成部分,相 纟且,有顯著較低的eosinophil浸潤比例。Penh=pause x PEF/PEF ; Pause=(Te - Tr) / Tr, (PIF : peak inspiratory flow; PEF : peak expiratory flow; Te : expiratory time; Tr : relaxation time) * : p < 0.05 # :P&lt ;0.1___ Table 9 C. Lung lavage fluid and lung cell analysis results The cellular components in the lung lavage fluid, compared to the control group, the experimental group fed with PM-A0006 lactic acid bacteria had significantly lower eosinophil infiltration. proportion. The results are summarized in Table 10, which is shown in Figure 8. Table 10 shows the lung washing solution group control group (%) Experimental group (%) eosinophil 27.5 ± 1.37 17.1 ± 1.66 (Ρ = 0.02) * % = In percentage 0 / 〇 * : P < 0.05 Table 10 D. Lung The cytokine analysis results of the rinsing liquid compared with the control group, the experimental group fed with PM-A0006 lactic acid bacteria can significantly reduce the amount of e〇taxin secretion in the lung rinsing and the tendency of pGE2& The results are summarized in Table 11, which is shown in Figure 9 and Figure 1 . Table η shows lung flushing cell stimulation [^ analysis results (Means ± Sg ^ [s. N = 14, P value = P) level: _ control χ, Α ^, Α ν χ / experimental group 38.8 ± 3.00 22.7 ± 1.54 (Ρ=0.02)* pge2 ---£__ 8.1±1.〇4 3.82±0.41(Ρ=0.08)# * : Ρ<0.05 21 201210509 Table 11 E. Spleen cell culture supernatant cytokine analysis results spleen After the cells were stimulated with ConA or egg protein (OVA) for 48 hours, IFN-γ secreted by the spleen's visceral cells of the experimental group fed with PM-A0006 lactic acid bacteria was significantly higher than that of the control group under ConA stimulation. The effect of stimulating substances on cytokine secretion of spleen cells (Means±SEMs, N=14, P value=P) group control group ConA 5185 558 9748±966(Ρ=〇·〇5,* * : PO.05 Table 12 Combining the above-mentioned 'electrochemical immunoassay test# of the invention_immunization reaction effectively overcomes the dry problem of electrochemical detection and improves the detection sensitivity In addition, the present invention can provide a single-step rapid test strip and quantitative detection, and further combines biotechnology and electronic secret processing to produce a low-cost technical test strip. The food composition of the present invention contains a summary Any combination of any one or more strains, such as milk powder, tea or coffee, can be stored in the composition / #(四) strain can live the dead bacteria (4) In addition to finding out that there is a specific function ϊ ίί = Wei Cai human stomach coffee (four) environment, ^ wants to have a good and allergic reaction to small intestinal mucosal epithelial cells with a strong anti-allergic lactic acid bacteria 匕 lh2 too rich. Invention of a 22 201210509 The goal is to provide the public with a new choice of steroids or anti-tissue ammonia in allergies. The present invention finds: = action and beneficial anti-allergic milk _ as the H-allergic system for allergy treatment The features of the present invention are described by way of examples, and the invention is intended to be understood by those skilled in the art of the invention. The modification or modification of the spirit of the disclosure should still be included in the scope of the patent application described below. [Simplified illustration of the schema] Figure 1 shows that when ίο6 to 108 cfil Lactobacillus acidophilus (Lactobacillus) Addophilus) PM-A0002 strain, Lactobacillus gasseri PM-A0005 strain, Lactobacillus salivarius subsp. salicinius PM-A0006 strain, Lactobacillus johnsonii PM-A0009 strain or acidophilus Lactobacillus acidophilus PM-A0013 strain was co-cultured with 1〇5 to 1 () 7 human peripheral white blood cells (PBMC) for 48 hours, and the cell supernatant was collected, ' Enzyme immunoassay was used to detect the interferon-gamma (IFN-gamma) in the supernatant. Among them, Lact〇bacillus casei BCRC12249 was used as the negative control group, and PHA was the positive control group. Interferon gamma is stimulated by concentration. The results showed that the experimental group significantly stimulated the secretion of interferon-gamma in human peripheral blood leukocytes (PBMC) and the negative control group. Figure 2 shows that 'when killing 1〇6 to 〇, respectively, cfU Lactobacillus acidophilus PM-A0002 strain, Lactobacillus gasseri PM-A0005 strain, salivary lactic acid Lactobacillus salivarius subsp. salicinius PM-A0006 strain, Lactobacillus johnsonii PM-A0009 strain or Lactobacillus acidophilus PM-A0013 strain and 1〇5 to 1〇7 human tree The dendritic cells were co-cultured for 48 hours, and the supernatant of the cells was collected, and the content of interleukin IL-12 in the supernatant was detected by an enzyme immunoassay. In 23 201210509, the lactic acid bacteria (Lact〇baciiius casei BCRC12249) was used as the control group, and PHA was used as the positive control group to detect the interleukin (IL_12) stimulated concentration. The test group can be based on the difference between the leucovorin (IW2) and the sputum (four) group (four). The force/graph shows that 'knot_the commercial anti-allergic lactic acid bacteria in the medium after the activation of the total number of bacteria via the acidic buffer solution and bile salt treatment, the number of bacteria decreased significantly; the patented lactic acid strain that regulates allergies after the medium was activated The strains, acidic buffer solution and bile salt, PM_A〇〇〇6, pM_A〇(), 9 and pM_AQQi3 were not significantly affected by changes in gastric choline, pM_A〇〇〇2 and ΡΜ·^ 0005 Although the number of bacteria affected by gastric acid proved to be resistant to gastric acid, when the strain was treated with bile salts, although the strain was slightly decreased, it was still tolerant to bile salts, demonstrating the five anti-allergic strains. Lactic acid strains can pass the test of the strict environment of the human body. Figure 4 shows that 'according to the analysis method of jac〇bsen et al. (1999), when the average g-number of visual fields is less than 40, it is judged to be unique (n_dhesive); when the average number of bacteria per field of view is 41 to When it was 1 ,, it was judged to be adherent; when the average number of bacteria per field of view was more than 1 ,, it was judged to be strongly adhesive. Lact〇baciUus acidophilus PM-A0002 strain, Lact〇baciUus gasseri PM-A0005 strain, Lactobacillus subtilis (Lact〇baciUussalivarius subsp. salicimus) PM-A0006 strain, Yogurt lactic acid Four strains of anti-allergic strains such as Lactobacillus johnsonii PM-A0009 strain were judged to be "strongly attached" and Lactobacillus acidophilus P]V [-A0013 strain was judged to be attached. 'Figure 5 shows that the anti-allergic lactic acid bacteria improve the design process of allergy experiments, the stage of feeding anti-allergic lactic acid bacteria is divided into four phases: the first phase is 〇~22 days; the second phase is 23~36 days; the third phase is 37 to 50 days; the fourth period is 51 to 53 days. In the meantime, mice were sensitized by intraperitoneal injection of ovalbumin (OVA), which was sensitized four times. The first time was 24 201210509 cm: 6 days; the third was started = 3 days, the fourth was: artificial tube The 44th day of Rao. Intraperitoneal injection of albumin (ovalbumm; 〇VA) sensitized mice will be bloody 4 weeks = sensitized mice for 2 consecutive days, _ mouse lung respiratory resistance response 'satually sacrificed mice every other day Detection of other biochemical values. =6 shows that the mice are supplemented with salivary lactic acid rod g ρΜ_Α〇_lactate protein-sensitized mouse serum egg protein (〇VA) specific anti-feeding fresh increase, prion protein (0VA) sensitized mice There is a tendency for the reduction of the [beta]-protein (OVA)-specific IgE antibody in serum. ^ 7 shows that the mouse is supplemented with salivary lactic acid rod g pM_A〇〇〇6 lactic acid strain = 夺 以, protein-sensitized mouse lung respiratory resistance, relative to the control = ' ^ can be in high concentration 醯 醯Low mouse Penh values stimulated by methach〇line. The #=8 image shows that the cells in the lung lavage fluid of the lactic acid-sensitized mouse larvae supplemented with Lactobacillus salivarius pM_A〇(8)6 lactate are relatively low in eosinophil infiltration ratio.

第9圖顯示,相對於對照組,餵食PM_A〇〇〇6乳酸菌 顯著降低肺沖洗中e〇taxin分泌量。 孔夂画T 第10圖顯示,相對於對照組,餵食ρμ_Α0006 ,著降低肺沖洗中簡2分泌量。 ==日2顯示,脾臟細胞經conA或卵蛋白(0VA)刺激培養 贴/二時後’在ConA刺激下,假食PM_A_6乳酸菌組之脾 ,胞分泌的干擾素γ顯著高於對敝。 f主要兀件符號說明】 無 25Figure 9 shows that feeding PM_A〇〇〇6 lactic acid bacteria significantly reduced the amount of e〇taxin secreted in the lung wash relative to the control group. Fig. 10 shows that, compared with the control group, feeding ρμ_Α0006 reduced the amount of Jane 2 secretion in lung washing. == Day 2 shows that spleen cells were stimulated by conA or egg protein (0VA). After 2 days, the spleen secreted by the PM_A_6 lactic acid bacteria group was significantly higher than that of the sputum. f main element symbol description] None 25

Claims (1)

201210509 七、申請專利範圍: L 一種生物性純培養物,其中該培養物係選自由下列組成之 群之菌株.嗜酸乳桿菌(Lactobacillus acid〇philus)pMA〇〇〇2(又名. Pf°-2).食品工業發展研究所寄存編號BCRC 910308 ;及嗜酸乳· 才干菌(Lactobacillus acidophilus)PM-A0013(又名 PRO-13):食品工業 發展研究所寄存編號BCRC 910309。 2. —種用於治療過敏之組合物’其包含促進__丫及正_12 分泌和減少IgE抗體、嗜伊紅白血球數量之至少一種乳酸桿菌株, 其中該乳酸桿菌株係選自由嗜酸乳桿菌(Lact〇baciUus add〇PhilUS)PM-A0002(又名PR0_2):食品工業發展研究所寄存編 號BCRC 910308及嗜酸乳桿菌(Lact〇bac胞s add〇Philus)PM-A0013(又名PR〇_l3):食品工業發展研究所寄存編 號BCRC 910309及其組合所組成之群。 3. 如申請專利範圍第2項之組合物’其中該等菌株係為活菌 或死菌。 4. 如申請專利範圍第2項之組合物,其中該組合物可添加於 食品中。 5. 如申請專利範圍第4項之組合物,其中該食品係選自由酿 酵乳、優格、乳酪、乳製飲品乳粉、茶及咖啡所組成之群。 6. 如申請專利範圍第1項之培養物,其中該培養物係指嗜酸 乳桿菌(Lactobacillus acidophilus)PM-A0002(又名 PR〇_2):食品工 業發展研究所寄存編號BCRC 910308。 < 7. 如申凊專利範圍第1項之培養物’其中該培養物係指邊酸 乳桿菌(Lactobacillus acidophilus)PM-A0013(又名 PR〇_i3):寄存編 號 BCRC 910309。 26201210509 VII. Patent application scope: L A biologically pure culture, wherein the culture is selected from the group consisting of Lactobacillus acid philus pMA〇〇〇2 (aka Pf°). -2). Food Industry Development Institute registration number BCRC 910308; and Lactobacillus acidophilus PM-A0013 (aka PRO-13): Food Industry Development Institute registration number BCRC 910309. 2. A composition for treating allergy comprising at least one strain of lactobacillus which promotes secretion of __丫 and _12 and reduces the number of IgE antibodies and eosinophils, wherein the strain of lactic acid is selected from an acidophilus Lactobacillus (Lact〇baciUus add〇PhilUS) PM-A0002 (aka PR0_2): Food Industry Development Institute registration number BCRC 910308 and Lactobacillus acidophilus (Lact〇bac s add〇Philus) PM-A0013 (aka PR 〇_l3): Group of Food Industry Development Institute registration number BCRC 910309 and its combination. 3. The composition of claim 2, wherein the strains are live or dead. 4. The composition of claim 2, wherein the composition is added to the food. 5. The composition of claim 4, wherein the food is selected from the group consisting of fermented milk, yogurt, cheese, dairy powder, tea and coffee. 6. The culture of claim 1, wherein the culture is Lactobacillus acidophilus PM-A0002 (aka PR〇_2): Food Industry Development Institute, registration number BCRC 910308. < 7. The culture of claim 1 wherein the culture refers to Lactobacillus acidophilus PM-A0013 (aka PR〇_i3): registration number BCRC 910309. 26
TW100139644A 2007-01-05 2007-01-05 Anti-allergy lactic acid bacteria TWI386163B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW100139644A TWI386163B (en) 2007-01-05 2007-01-05 Anti-allergy lactic acid bacteria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW100139644A TWI386163B (en) 2007-01-05 2007-01-05 Anti-allergy lactic acid bacteria

Publications (2)

Publication Number Publication Date
TW201210509A true TW201210509A (en) 2012-03-16
TWI386163B TWI386163B (en) 2013-02-21

Family

ID=46764016

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100139644A TWI386163B (en) 2007-01-05 2007-01-05 Anti-allergy lactic acid bacteria

Country Status (1)

Country Link
TW (1) TWI386163B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113521114A (en) * 2020-03-31 2021-10-22 丰华生物科技股份有限公司 Composition for resisting oxidation, protecting oral cavity, regulating immunity and promoting movement and application thereof
TWI788840B (en) * 2021-05-10 2023-01-01 我的輕食有限公司 The lactobacillus acidophilus strain tw01, probiotics composition thereof, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI277651B (en) * 2002-09-02 2007-04-01 Genmont Biotech Inc New use of some lactobacillus strains in treating allergy
KR101312745B1 (en) * 2005-03-03 2013-09-27 가부시키가이샤 메이지 Immune function modulating agents

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113521114A (en) * 2020-03-31 2021-10-22 丰华生物科技股份有限公司 Composition for resisting oxidation, protecting oral cavity, regulating immunity and promoting movement and application thereof
CN113521114B (en) * 2020-03-31 2023-08-04 丰华生物科技股份有限公司 Composition for resisting oxidation, protecting oral cavity, regulating immunity and promoting movement and application thereof
TWI788840B (en) * 2021-05-10 2023-01-01 我的輕食有限公司 The lactobacillus acidophilus strain tw01, probiotics composition thereof, and use thereof

Also Published As

Publication number Publication date
TWI386163B (en) 2013-02-21

Similar Documents

Publication Publication Date Title
TWI356680B (en) Anti-allergy lactic acid bacteria
CN114032193B (en) Lactobacillus paracasei 207-27 and application thereof
AU2021333530B2 (en) Bifidobacterium breve 207-1 and use thereof
JP5069556B2 (en) T cell apoptosis inducer
TWI304736B (en)
TWI542353B (en) Anti-vaginitis food composition and pharmaceutical composition containing lactobacillus
CN101328468B (en) Antiallergic lactic acid bacteria
JP6985342B2 (en) Bifidobacterium Lactis GKK2, a composition containing it, and its use for allergic asthma amelioration
Matsumoto et al. Anti-inflammatory metabolite production in the gut from the consumption of probiotic yogurt containing Bifidobacterium animalis subsp. lactis LKM512
Nishihira et al. Lactobacillus gasseri SBT2055 stimulates immunoglobulin production and innate immunity after influenza vaccination in healthy adult volunteers: a randomized, double-blind, placebo-controlled, parallel-group study
WO2012075684A1 (en) Lactobacillus strains and use thereof for regulating immune response
TWI398259B (en) Composition and use of lactobacillus paracasei strain gmnl-133 in treating atopic dermatitis or other allergic diseases
CN102028224B (en) Antiallergic lactobacillus
TW201210509A (en) Anti-allergy lactic acid bacteria
JP4479162B2 (en) Immune function regulator and immune function-modulating food
TWI429444B (en) Novel lactobacillus strains and their uses for modulating immune response
CN113005066B (en) Compound bifidobacterium preparation for resisting allergy, increasing immunity, reducing blood sugar and fat and losing weight and preparation method thereof
TWI400076B (en) Novel use of sevral lactic acid bacteria in the treatment of allergy
EP2332557A1 (en) Probiotic lactic acid bacteria
TWI355272B (en) Food and pharmaceutical composition with strains o
CN102657260B (en) Antiallergic lactobacillus
JP2006257040A (en) INHIBITOR FOR PRODUCTION OF ALLERGEN-SPECIFIC IgE ANTIBODY AND FOOD AND BEVERAGE USED FOR SUPPRESSING THE PRODUCTION OF THE ALLERGEN-SPECIFIC IgE ANTIBODY
Samsidi et al. Synbiotic and nutrients supplement improved of Secretory Immunoglobulin A (sIgA) in treated pulmonary tuberculosis patients
CN117625435A (en) Lactic acid bacteria and use thereof for medicaments for preventing or treating allergies
TWI381843B (en) Food and pharmaceutical composition with strains of heat-killed bacteria for treament of allergy